Precision and predictive medicine in urothelial cancer: are we making progress?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 25935702.
- Also identified by DOI 10.1016/j.eururo.2015.04.025.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Therapy for urothelial carcinoma appears poised for a breakthrough on the basis of information regarding molecular subtypes and promising activity of PD-1/PD-L1 inhibitors. Precision medicine may be possible using rational marker-driven trial designs with enriched information from tumor genotyping and extreme responders.
Medical subject headings
- Antineoplastic Agents
- Biomarkers, Tumor
- Molecular Targeted Therapy
- Precision Medicine
- Urinary Bladder Neoplasms
- Urothelium